Shows
Medsider: Learn from Medtech and Healthtech Founders and CEOsHow to Navigate Clinical Trials and Fundraising Challenges: Interview with Eyevensys CEO Patricia ZillioxIn this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, who has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.Before we jump into the conversation, I wante...2022-01-1921 min
Mastering Medical DeviceWhy a Device and Biologic Combination Product is a Challenge and an Opportunity with Patricia ZillioxSend us a textPatricia Zilliox has devoted her career to solving problems with the eyes. She had a very successful career at Alcon, then at the Foundation Fighting Blindness Clinical Research Institute, before joining Eyevensys as CEO. Eyevensys is working on a technology that has the potential to solve a big problem. In this episode Patricia shares how a biologics company approaches device design and manufacture, combination product development, the regulatory pathway, funding challenges, how device differs but is similar to pharma and biologics, and how great companies retain great people. Links from this ep...2022-01-0451 min
OIS Podcast | Ophthalmology's leading PodcastAu Petit Bonheur La ChanceThis week’s OIS Retina Podcast guest is French-born Patricia Zilliox, who boomeranged back to her homeland to become president and CEO of Eyevensys. Before that she’d spent 25 years with Alcon before joining the Foundation Fighting Blindness as chief drug development officer. When a family matter brought her back to France, she was introduced to Eyevensys through the investment group BPI France. Having spent so much time evaluating new therapies at FFB, she was intrigued by Eyevensys’ unique platform to enable the sustained intraocular production of therapeu...2020-08-1329 min